Approvals & regulatory · first seen 12h ago, updated 6h ago
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin1,2 With Onswik, Lilly's type 2 diabetes portfolio expands to include a once-weekly basal insulin, alongside existing treatment options across insul…
Summary from PR Newswire - FDA Approval.
Coverage 4 articles · 4 outlets
-
PR Newswire - FDA ApprovalU.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
-
Pharmaceutical Executive
-
Drug Topics
-
Pharmacy Times